BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?

@article{Dunleavy2007BCL6AR,
  title={BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?},
  author={Kieron Dunleavy and Ricardo Davis and Ola Landgren and Louis M. Staudt and Wyndham H. Wilson},
  journal={Blood},
  year={2007},
  volume={109 2},
  pages={843-4; discussion 844-5}
}
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? We read with interest the paper by Winter et al 1 in which they report the impact of BCL-6 protein expression on outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with cyclophospha-mide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab (R-CHOP) or without. These findings provide potentially important insights into DLBCL treatment and rituximab action. Perhaps most revealing is the apparent… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Is it time to stop treating subsets of DLBCL with R - CHOP ?

C Moskowitz
Blood • 2006

Long - term results of the R - CHOP study in the treatment of elderly patients with diffuse large B - cell lymphoma : a study by the Groupe d ’ Etude des Lymphomes de l ’ Adulte

P Feugier, A VanHoof, C Sebban
J Clin Oncol • 2005

Molecular profiling of diffuse large B - cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

S Monti, KJ Savage, JL Kutaok
Blood • 2005

Dose - adjusted EPOCH - rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B - cell lymphoma [ abstract ]

WH Wilson, K Dunleavy, S Pittaluga
Blood • 2004

Similar Papers

Loading similar papers…